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Abstract
Purpose Previous studies indicate a possible inverse rela-
tionship between prostate-specific antigen (PSA) and body
mass index (BMI), and a positive relationship between PSA
and age. We investigated the associations between age,
BMI, PSA, and screen-detected prostate cancer to determine
whether an age–BMI-adjusted PSA model would be clini-
cally useful for detecting prostate cancer.
Methods Cross-sectional analysis nested within the UK
ProtecT trial of treatments for localized cancer. Of 18,238
men aged 50–69 years, 9,457 men without screen-detected
prostate cancer (controls) and 1,836 men with prostate
cancer (cases) met inclusion criteria: no history of prostate
cancer or diabetes; PSA\ 10 ng/ml; BMI between 15 and
50 kg/m2. Multivariable linear regression models were
used to investigate the relationship between log-PSA, age,
and BMI in all men, controlling for prostate cancer status.
Results In the 11,293 included men, the median PSA was
1.2 ng/ml (IQR: 0.7–2.6); mean age 61.7 years (SD 4.9);
and mean BMI 26.8 kg/m2 (SD 3.7). There were a 5.1%
decrease in PSA per 5 kg/m2 increase in BMI (95% CI
3.4–6.8) and a 13.6% increase in PSA per 5-year increase
in age (95% CI 12.0–15.1). Interaction tests showed no
evidence for different associations between age, BMI, and
PSA in men above and below 3.0 ng/ml (all p for inter-
action [0.2). The age–BMI-adjusted PSA model per-
formed as well as an age-adjusted model based on National
Institute for Health and Care Excellence (NICE) guidelines
at detecting prostate cancer.
Conclusions Age and BMI were associated with small
changes in PSA. An age–BMI-adjusted PSA model is no
more clinically useful for detecting prostate cancer than
current NICE guidelines. Future studies looking at the
effect of different variables on PSA, independent of their
effect on prostate cancer, may improve the discrimination
of PSA for prostate cancer.
Keywords Prostate cancer  PSA  BMI  Age  Prostate
cancer screening  PSA–BMI equation
Background
Prostate cancer is the second most common cancer in men
worldwide, with 1.1 million new cases diagnosed in 2012
[1]. Although prostate cancer deaths are considerably fewer
in number than incident cancers (307,000 deaths world-
wide in 2012 [1]), prostate cancer is the fifth leading cause
of death from cancer in men. Developed countries tend to
have a higher incidence of prostate cancer than others, in
part due to increasing and widespread testing for serum
prostate-specific antigen (PSA) [1].
There is considerable controversy over the effectiveness
of PSA screening for prostate cancer [2–6]. One issue
affecting the accuracy of the PSA test is that it is influenced
by many variables other than the presence of cancer, for
example diet [7], ethnicity [8], genetic variation [9, 10],
certain drugs [11–14], and non-malignant disease [15–17].
Several studies report an inverse relationship between PSA
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and body mass index (BMI) [18–23], which may explain
the observed inverse relationship between BMI and inci-
dent prostate cancer [24]. However, studies suggest the
observed inverse relationship is a result of confounders and
is eliminated in multivariable models (adjusted for age,
current statin, aspirin and other NSAID use, diabetes, and
benign prostatic hyperplasia) [25]. Most studies also report
an increase in PSA with age [18].
The explanation for the positive relationship between
age and PSA is well understood; with age, the prostate
enlarges and contains more PSA-producing tissue. Older
prostates tend to leak more PSA because the normal
physiologic barriers breakdown, which allows PSA to
escape into capillaries leading to a slight increase in serum
PSA concentration [26]. Here, the degeneration of prostatic
cells is independent of prostate cancer; although degener-
ation may increase cancer risk over time, the increase in
PSA caused by the degeneration is therefore not directly
caused by cancer.
The explanation for the inverse relationship between
BMI and PSA levels is more uncertain; one suggestion is
that obesity causes hemodilution due to an increased
plasma volume [22, 27, 28]; another is that reduced
androgen levels and increased estrogen in overweight men
cause lower circulating PSA levels [23]. The reduction in
PSA caused by an increased BMI may lead to men not
receiving a biopsy when a smaller man would, which may
help explain the observed paradoxical inverse relationship
of BMI with prostate cancer detection, but the positive
relationship between BMI and increased prostate cancer
mortality [24]. However, it is difficult to establish whether
obesity affects prostate cancer directly or whether its effect
on PSA means obese men are diagnosed later with an
associated worse prognosis.
In current UK practice, PSA value thresholds are used
when screening for prostate cancer to indicate further
investigation by prostate biopsy. National Institute for
Health and Care Excellence (NICE) guidelines advise using
age-specific cutoff PSA measurements: for men aged
50–59 years C3.0 ng/ml; 60–69 years C4.0 ng/ml; 70 years
and older C5.0 ng/ml [29]. However, BMI is not taken into
account when considering whether to send a man for biopsy.
Prostate cancer risk calculators (ERSPC risk calculator 6
[30], the Prostate Cancer Prevention Trial (PCPT) risk
calculator [31], and PSA-AV developed by Patel et al.
[32]) take age into account when considering prostate
cancer risk and are available in the literature and on the
Internet. The PCPT risk calculator can also include BMI
category [33]; the BMI-adjusted PSA for a man is calcu-
lated by multiplying his PSA by the ratio of the geometric
mean of PSA for BMI\25 to the geometric mean of PSA
for his BMI category.
The majority of men undergoing PSA tests in the UK are
likely to be overweight or obese [34]. If the inverse PSA–
BMI relationship is considerable, having a PSA threshold
which decreases with increasing BMI (adjusting the PSA
for BMI) may improve the accuracy of the test for
detecting prostate cancer. The aim of this study was to
examine the relationship between PSA and BMI in a large
population-based study of men undergoing PSA tests, to
derive a model to adjust the observed PSA for the rela-
tionship between BMI, age, and PSA and investigate
whether an age–BMI-adjusted model for PSA would be
clinically useful for detecting prostate cancer.
Materials and methods
We conducted a cross-sectional study nested within Pro-
tecT (Prostate testing for cancer and Treatment), a popu-
lation-based randomized controlled trial which compares
treatments for clinically localized prostate cancer. Study
details are published elsewhere [35]. In brief, 225,000 men
aged 50–69 in 9 centers across the UK were invited for
PSA testing. Of the 111,000 men who attended a PSA test,
10,000 had a PSA C3.0 ng/ml: Those with a PSA\20 ng/
ml were invited for a 10-core transrectal ultrasound-guided
biopsy, a repeat PSA test, and a digital rectal exam, while
men with a PSA over 20 ng/ml were referred to usual care.
Those with clinically localized PCa were invited into the
ProtecT randomized treatment trial, comparing radical
surgery, radical conformal radiotherapy and active moni-
toring [35].
We selected all 3,096 men diagnosed with prostate
cancer and a random sample of 18,231 men without
prostate cancer and with full information on covariates.
The random sample was generated prior to this study by
matching cases with 6 men without prostate cancer from
within the same 5-year age band and GP practice. All
potential matches were ordered by computer-generated
random numbers, and the first 6 controls were chosen as a
match. Men without prostate cancer were defined as
having received a PSA test with no subsequent histolog-
ical confirmation of prostate cancer, either because they
were not indicated for biopsy (PSA\ 3.0 ng/ml) or
because a 10-core biopsy was negative (PSA C 3.0 ng/
ml). All men provided written informed consent prior to
inclusion in the study. Trent Multicentre Research Ethics
Committee (MREC) approved the ProtecT study (MREC/
01/4/025) and the associated Prostate Mechanisms of
Progression and Treatment (ProMPT) study which col-
lected height data (MREC/01/4/061) as part of a diet,
health and lifestyle questionnaire. All data were anon-
ymized prior to analysis.
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Inclusion and exclusion criteria
For men without prostate cancer, the inclusion criteria for this
analysis were: age between 50 and 69 years with no previous
history of prostate cancer or diabetes, a BMI between 15 and
50 kg/m2, and PSA B 10.0 ng/ml. Of the 18,231 men with-
out prostate cancer, 9,457 (52%) satisfied the inclusion cri-
teria. Most excluded men lacked data on height (n = 6,916,
38%) to compute BMI, as height datawere collected as part of
a separate questionnaire not filled in by all ProtecT partici-
pants and thus were likely missing at random.
Men with diabetes and men with no information on dia-
betes status (n = 1,572, 8.6%) were excluded, because
diabetes influences PSA levels, prostate cancer risk and is
associated with BMI [20, 36]. Men with a PSA above
10.0 ng/ml were excluded (n = 33, 0.2%), as high PSA
levels can be associated with increased risk of false nega-
tives at prostate biopsy [37]. A value of 10.0 ng/ml was
chosen as the threshold as it compromises between exclud-
ing those most as risk of having a false negative at prostate
biopsy and keeping as many men as possible in the analysis.
For men with prostate cancer, the inclusion criteria for
this analysis were: age between 50 and 69 years, no pre-
vious history of diabetes, and a BMI between 15 and 50 kg/
m2. Of the 3,096 men with prostate cancer, 1,830 (59%)
satisfied the inclusion criteria; most excluded men lacked
height data to compute BMI (n = 931, 30%), and 280 men
with diabetes were excluded (9%).
For all men without height data (n = 7,847), the average
age and weight were 61.1 years and 86.4 kg, slight dif-
ferences to men with height data (n = 13,412), 62.0 years
and 85.0 kg (both p\ 0.01). Men with prostate cancer
were more likely to have height data, 70 versus 62% of
men without prostate cancer. The mean PSA for men
without prostate cancer but with height data was 1.39 ng/
ml, slightly more than for men without prostate cancer and
height data, 1.28 ng/ml (p\ 0.01). Conversely, the mean
PSA for men with prostate cancer and height data was
9.47 ng/ml, slightly less than for men with prostate cancer
but without height data, 10.78 ng/ml (p = 0.21).
For men without prostate cancer only, men with diabetes
(n = 1,029) had an average age of 63.2 years, BMI of
29.9 kg/m2, and PSA of 1.23 ng/ml, whereas men without
diabetes (n = 11,772) had a lower average age (61.8 years),
BMI (27.2 kg/m2), and higher PSA (1.39 ng/ml). Men with
missing diabetes status (n = 8,526) had an average age of
61.3 years, BMI of 27.6 kg/m2, and PSA of 1.30 ng/ml.
Statistical analysis
The BMI of each man was calculated by dividing their
weight (in kg) by their height squared (in meters squared).
94% of the men were weighed at clinic by a nurse, but 6%
of men only had self-reported weights in stones and pounds
as part of a diet, health and lifestyle questionnaire. Height
was self-reported in feet and inches. Self-reported weight
and height measurements were converted from imperial to
metric units when calculating BMI.
The data from the 9,457 men without prostate cancer
and 1830 men with prostate cancer were used to derive a
model associating age and BMI with PSA. A multiplicative
model for PSA was assumed, where the relationships
between PSA and age and BMI were dependent on an
initial level of PSA; a change in age or BMI leads to a
proportional change in PSA.
A multiplicative model is intuitively more appropriate
than an additive model, as a man with a high PSA would be
expected to have a larger change in PSA than a man with a
low PSA for the same change in age or BMI. Multivariable
linear regression of the natural logarithm of PSA against
age, BMI, and case–control status, separately and together
in univariable and multivariable models, was used to esti-
mate the coefficients for the model. Case–control status
was included as a covariate to account for any associations
between age and BMI with prostate cancer, which would
otherwise bias the results.
The model was used to derive ‘‘adjusted’’ PSAs,
removing the effects of age and BMI on PSA separately
and together. The adjustment changes the man’s observed
PSA by an amount depending on the man’s observed PSA
and the difference between the man’s age or BMI and the
mean age and BMI in this study. The larger the difference
between the man’s age or BMI from the study mean, and
the larger the observed PSA, the more the observed PSA is
altered. The adjusted PSA can be interpreted as what the
man’s PSA would have been, if they had been of average
age and BMI.
The equation to adjust PSA for age and BMI is shown
here:
Age=BMI adjusted PSA ¼ PSA
e a  agecoefþb  BMIcoefð Þ
where age–BMI-adjusted PSA is PSA adjusted for age and
BMI, PSA is a man’s observed prostate-specific antigen in
ng/ml, a is the difference between the man’s age and the
population mean age in years, b is the difference between
the man’s BMI and the population mean BMI in kg/m2,
agecoef is the coefficient of age from our linear regression
model, BMIcoef is the coefficient of BMI from our linear
regression model, and e is the exponential function. This
model assumes that the relationship between PSA and BMI
and age is the same for men with and without prostate
cancer, in this population.
The age–BMI-adjusted PSA was used to determine
whether the adjustment of PSA for BMI and age was
Cancer Causes Control (2016) 27:1465–1474 1467
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clinically useful for detecting prostate cancer. Sensitivity
and specificity estimates were calculated for the use of PSA
to detect prostate cancer at biopsy (see Box 1). These used
thresholds of 3.0 and 4.0 ng/ml (commonly used thresholds
in clinical practice in the UK) for observed PSA values,
age-adjusted PSA, BMI-adjusted PSA, age- and BMI-ad-
justed PSA, and were also compared to the sensitivity and
specificity of the UK NICE guideline thresholds for PSA
testing [29].
Sensitivity and specificity
The sensitivity was calculated as the number of men with
diagnosed prostate cancer who had a PSA above the
threshold level divided by the total number of men with
diagnosed prostate cancer (PSA-positive cases/total cases).
The specificity was calculated as the number of men
without diagnosed prostate cancer who had a PSA below
the threshold level divided by the total number of men
without prostate cancer (PSA-negative controls/total
controls).
Men with a PSA below 3 ng/ml may have undiagnosed
prostate cancer, as they were not biopsied. In the Prostate
Cancer Prevention Trial (PCPT), 17% (n = 759) of men
with a PSA below 3 ng/ml had prostate cancer on biopsy
[31]. As the ages and BMIs of men in the PCPT were
different from ProtecT, it is difficult to estimate the
number of men in ProtecT who had undiagnosed prostate
cancer.
Because some men will not have been biopsied but will
have undiagnosed prostate cancer, the calculated sensitiv-
ities in this study will be higher than the true sensitivities.
Additionally, even men who received a biopsy may also
have had undiagnosed prostate cancer due to the sensitivity
of 10-core biopsy; Haas demonstrated that a 12-core biopsy
of cadavers showed a sensitivity for all prostate cancers of
between 36 and 53%, depending on sampling location
within the prostate [38]. The sensitivity of 12-core biopsy
rises to 80 and 85% for ‘‘clinically significant’’ and large
(C0.5 cm3) cancers, respectively. The specificity of biopsy
was 99%, indicating there should be few incorrect diag-
noses of prostate cancer.
Therefore, the total number of men with prostate cancer
is underestimated in this study, both by men not receiving a
biopsy and by the biopsy not detecting all cancers, so the
sensitivity of each PSA test will be overestimated (see
Box 2). The total number of men without prostate cancer is
overestimated in this study by the same amount, but this is
unlikely to affect the specificity as there are far more men
without than with prostate cancer. However, the main
analysis will focus on the 4.0 ng/ml threshold; as the
biopsy threshold in ProtecT was 3 ng/ml almost all men
who might change over a 4.0 ng/ml threshold will have
been biopsied. Assuming there is no strong relationship
between PSA and missing prostate cancer at biopsy, this
means any change in sensitivity or specificity seen in the
PSA models is unlikely to be affected by men with undi-
agnosed prostate cancer. Therefore, all PSA models in this
study can be directly compared, even though they do not
represent the true sensitivity of PSA as a test for prostate
cancer.
NICE guidelines use different thresholds for different
age groups, making it difficult to directly compare the
sensitivity and specificity to the other models. To show
clinical utility, our PSA models would require both a
higher sensitivity and specificity; otherwise, there would
be a trade of specificity for sensitivity, or vice versa.
Therefore, the sensitivity of all models was compared at
the same specificity seen when using the NICE guidelines;
any model with a higher sensitivity would necessarily be
more clinically useful. McNemar’s test was used to
determine whether any model was preferred over the
NICE guidelines [39] when the specificities of all models
were equal.
As the sensitivities and specificities of the models are
likely to be inaccurate, ROC curves (receiver operating
characteristics) [40] and area under the curves (AUCs)
were not generated.
Tenfold cross-validation [41] was used to determine
whether the sensitivities and specificities of the adjusted
PSAs were consistently better or worse than the NICE
guideline thresholds for PSA testing. In tenfold validation,
the dataset is split into 10 equal parts and each part of the
dataset is considered the ‘‘validation’’ dataset, with the
other 9 parts used to calculate the model that will be val-
idated. This is repeated 10 times, until each part of the
dataset has acted as the ‘‘validation’’ dataset. The sensi-
tivities and specificities of each model were averaged
across the 10 validations, with the mean and standard
deviation recorded. These were then compared across
models to give a robust indication of the performance of
each model. The advantage of using tenfold cross-valida-
tion as opposed to split-cohort validation is that the training
data can be as large as possible without compromising the
robustness of the model performance in the testing data.
An interaction test [42] was performed to determine
whether there was a difference in the associations between
age, BMI, and PSA for men with PSA values above and
below 3 ng/ml; this was to test whether the undiagnosed
prostate cancers from men not being biopsied were causing
any bias in the results. Multivariable regressions were
performed as above, restricted to men with a PSA above
1468 Cancer Causes Control (2016) 27:1465–1474
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and below 3.0 ng/ml separately. For both age and BMI, the
difference in coefficients was divided by the combined
standard error to give a Z-score, which was converted to a
p value.
Gleason score was used as an additional outcome in men
with diagnosed prostate cancer, and ordered logistic
regression was used to determine whether age and BMI
were associated with Gleason score in this population. In
order to examine the sensitivity of conclusions to the rel-
ative proportions of cases and controls, we re-ran all pri-
mary analyses using only controls to derive the age- and
BMI-adjusted PSA, and then examined the sensitivity and
specificity of this model. A further sensitivity analysis used
multiple imputations by the MICE system of chained
equations to estimate missing BMI and diabetes data from
weight, height, age, case–control status, diabetes status,
and log-PSA to determine whether missing height/diabetes
would likely have caused bias.
All analyses were performed using Stata 13.1 (Stata-
Corp, TX).
Results
Summary demographics are presented in Table 1. The
mean age for all men (n = 11,293), cases (n = 9,457), and
controls (n = 1,836) was 61.7 (SD 4.9), 61.6 (SD 4.9), and
61.8 (SD 4.9) years, respectively. The mean BMI was 27.2
(SD 3.7), 27.2 (SD 3.8), and 27.1 (SD 3.6) kg/m2,
respectively (p = 0.21). The median PSA was 5.0 ng/ml
(IQR 3.7–8.0) in cases and 1.0 ng/ml (IQR 0.6–1.7) in
controls (p\ 0.0001). Ordered logistic regression of 1,830
men with a Gleason score with age and BMI showed both
were weakly associated with Gleason score: age: coef =
0.03, p = 0.002; BMI: coef = 0.03, p = 0.04.
In univariable models (n = 11,293), where log-PSA was
regressed separately against age and BMI (with case–
control status as a covariate), PSA increased by 13.55%
(95% CI 12.01–15.11) per 5-year increase in age and
decreased by 5.58% (95% CI 3.83–7.29) per 5 kg/m2
increase in BMI. When case–control status was omitted
from the regression, PSA increased by 14.30% (95% CI
Box 1 Definitions of sensitivity and specificity
Sensitivity—the true positive rate; the number of people with prostate cancer who had a PSA above the threshold level divided by the total
number of people with diagnosed prostate cancer
Specificity—the true negative rate; the number of people without prostate cancer who had a PSA below the threshold level divided by the
total number of people without prostate cancer
Box 2 Effect of undiagnosed prostate cancer on sensitivity and specificity of PSA testing for prostate cancer. Bold letters are the true number of
men in each cell, and italic letters are the study number of men in each cell
Prostate cancer No prostate cancer








Number of men with (left) and without (right) prostate cancer A 1 C
A - x
B 1 D
B ? x ? D ? C
A and C are the number of men truly with prostate cancer, B and D are the number of men truly without prostate cancer, and x is the number of
men with prostate cancer but the biopsy missed the cancer.
Men with a PSA above 3.0 ng/ml were biopsied, so any underestimation in A and overestimation in B is from biopsies that miss the cancer [38].
If there are x men with missed cancers, then A becomes A - x and B becomes B 1 x.
Men were not biopsied if their PSA was less than 3.0 ng/ml, so C becomes 0. Some men will have prostate cancer and a PSA less than 3.0 ng/ml
[31], so C is underestimated and D becomes D 1 C.
As C is 0, all calculated sensitivities [A/(A 1 C)] with a PSA threshold of 3.0 ng/ml or less will be 1. In this study, the sensitivity will always be
overestimated, as the total number of men with prostate cancer (A 1 C) will always be underestimated.
The specificity [D/(B 1 D)] may be over- or underestimated as both B and D are overestimated by different amounts, but overall the calculated
specificity should not differ too much from the true specificity.
Example: 2,500 men truly had prostate cancer (A 1 C), but 100 were missed at biopsy (x) and 500 had a PSA less than 3.0 ng/ml (C) so were
not biopsied, and 7,500 men truly did not have prostate cancer (B 1 D); 1,000 of these men had a PSA greater than 3.0 ng/ml (B).
The calculated sensitivity at 3.0 ng/ml would be (Ax)/(A - x) = (2,000-100)/(2,000-100) = 1, but the true sensitivity would be A/
(A 1 C) = 2000/2500 = 0.8; the sensitivity is overestimated.
The calculated specificity at 3.0 ng/ml would be (D 1 C)/(B 1 x ? D 1 C) = (6,500 ? 500)/(1,000 ? 100 ? 6,500 ? 500) = 0.86, and the
true specificity would be D/(B 1 D) = 6,500/7,500 = 0.87; the specificity is very close to the true value.
Cancer Causes Control (2016) 27:1465–1474 1469
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12.22–16.41) per 5-year increase in age and decreased by
6.55% (95% CI 4.24–8.81) per 5 kg/m2 increase in BMI.
In the multivariable model (n = 11,293), where log-
PSA was regressed against BMI, adjusting for age and
case–control status together, there was a 5.14% decrease in
PSA per 5 kg/m2 increase in BMI (95% CI 3.41–6.84,
p\ 0.001) (Table 2). The BMI-adjusted results for age are
not presented, as there is no plausible mechanism by which
BMI can confound the age–PSA association.
The sensitivities and specificities (as defined by the
proportion of cases above the threshold PSA and the pro-
portion of controls below the threshold PSA, respectively),
of the different PSA models at 3.0 and 4.0 ng/ml thresh-
olds, and the NICE guidelines (threshold dependent on age)
are presented in Table 3. All sensitivities and specificities
were calculated assuming no undiagnosed prostate cancers
among men in the control group or misdiagnosis by biopsy
and are thus inaccurate (the sensitivities are overestimates,
Table 1 Summary
demographics of included
participants; cases have a
diagnosis of prostate cancer
All Cases Controls p value for difference
n 11,293 1,836 9,457 NA
Age (SD) 61.7 (4.94) 61.8 (4.90) 61.6 (4.95) 0.29
BMI (SD) 27.2 (3.73) 27.1 (3.57) 27.2 (3.76) 0.21
PSA (IQR) 1.2 (0.7–2.6) 5 (3.7–8.0) 1 (0.6–1.7) \0.0001
BMI categories in kg/m2 [n (%)]
\25 3,274 (29) 522 (28.4) 2,752 (29.1) p for trend = 0.65
25–29.9 5,805 (51.4) 979 (53.3) 4,826 (51)
[30 2,214 (19.6) 335 (18.3) 1,879 (19.9)
Table 2 Results of linear




Variable n Change in PSA (%) Log(PSA) change per 5 unit increase in covariate
Coefficient p value 95% CI
Univariable
Age 11,293 13.55 0.127 \0.00001 0.113 to 0.141
BMI 11,293 -5.58 -0.057 \0.00001 -0.076 to -0.039
Multivariable
Age 11,293 13.43 0.126 \0.00001 0.112 to 0.140
BMI 11,293 -5.14 -0.053 \0.00001 -0.071 to -0.035
The beta coefficients for change in log-PSA are equivalent to the logarithm of the multiplicative change in
PSA per 5 unit increase in age–BMI, which has been expressed as a percentage change in the table. Small
change in log-PSA is broadly interpretable as the percentage changes in PSA
PSA prostate-specific antigen, BMI body mass index, SE standard error
Table 3 Sensitivities (proportion of men diagnosed with prostate cancer (cases) above the threshold PSA) and specificities (proportion of men
not diagnosed with prostate cancer (controls) below the threshold PSA) for prostate cancer detection at biopsy for different models
Model Threshold 3.0 ng/ml Threshold 4.0 ng/ml
Proportion of cases above
threshold
Proportion of controls below
threshold
Proportion of cases above
threshold
Proportion of controls below
threshold
Observed 1 0.931 0.687 0.964
Age–PSA 0.947 0.932 0.699 0.968
BMI–PSA 0.978 0.932 0.682 0.965
Age–BMI–PSA 0.942 0.932 0.708 0.967
NICE
guidelinesa
– – 0.797 0.958
PSA prostate-specific antigen, BMI body mass index
a NICE guidelines–ages 50–59: 3.0 ng/ml, ages 60–69: 4.0 ng/ml
1470 Cancer Causes Control (2016) 27:1465–1474
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and the specificities may be over- or underestimates, as
explained in Box 2).
Compared to PSA alone, sensitivity was improved when
adjusting PSA for BMI [by about 0.01 (1%)], but speci-
ficity worsened at both 3.0 and 4.0 ng/ml thresholds [by
0.003 (0.3%) and 0.001 (0.1%), respectively]. In compar-
ison, adjusting PSA for age improved both the sensitivity
and specificity at 4.0 ng/ml [by 0.026 (2.6%) and 0.002
(0.2%), respectively], but worsened both sensitivity and
specificity at 3.0 ng/ml [by 0.021 (2.1%) and 0.003 (0.3%),
respectively]. Adjusting PSA for both age and BMI showed
similar results to adjusting solely for age, with the excep-
tion of improved sensitivity at 4.0 ng/ml, implying that
adjusting for BMI as well as age did not materially improve
the discrimination of PSA for prostate cancer.
When the specificity of the model PSAs was set to the
same as the NICE guidelines (0.958), the sensitivities were
all below that of the NICE guidelines: NICE: 0.797; PSA
alone: 0.768; age-adjusted PSA: 0.794; BMI-adjusted PSA:
0.758; and age–BMI-adjusted PSA: 0.796. However, when
each model was compared with the NICE guidelines using
McNemar’s test, there was no evidence to say any model
was better or worse at detecting prostate cancer: PSA alone
p value 0.65; age-adjusted PSA p value: 1; BMI-adjusted
PSA p value: 0.53; age–BMI-adjusted PSA p value: 1.
The tenfold cross-validation showed that the averaged
sensitivities and specificities were very close to the sensi-
tivities and specificities of the results from the main anal-
ysis. The standard deviations were low, indicating the
models performed robustly across the ten validation sets
(Table 4). Therefore, it is unlikely that the results from the
main analysis are the product of validating the models in
the same dataset used to develop the models.
The interaction test examining whether men with a PSA
at or above 3.0 ng/ml (n = 2,489) had different estimates
of the associations between age, BMI, and PSA to men
with a PSA less than 3.0 ng/ml (n = 8,804) showed no
evidence of an effect of not receiving a biopsy; the p value
for the interactions with age and BMI, respectively, was
0.22 and 0.24.
In the sensitivity analysis using only men without
prostate cancer (n = 9,457), multivariable linear regression
showed a 5.51% decrease in PSA per 5 kg/m2 increase in
BMI (95% CI 3.62–7.36) and univariable regression
showed a 14.25% increase in PSA per 5-year increase in
age (95% CI 12.54–15.98). Sensitivity and specificity for a
threshold of 3 ng/ml were 0.900 and 0.898 and for a
threshold of 4 ng/ml were 0.673 and 0.930, respectively.
These results indicate that while the sensitivities and
specificities were slightly less than the full model (3 ng/ml:
0.942, 0.932; 4 ng/ml: 0.708, 0.967), the association
between PSA and age and BMI in men without prostate
cancer in this population is similar to that in the entire
population.
In the sensitivity analysis where BMI and diabetes data
were imputed (n = 19,524), multivariable linear regression
showed a 5.22% decrease in PSA per 5 kg/m2 increase in
BMI (95% CI 3.67–6.80) and univariable regression
showed a 13.33% increase in PSA per 5-year increase in
age (95% CI 12.14–14.54). Averaged sensitivity and
specificity over ten imputations for a threshold of 3 ng/ml
were 0.941 and 0.938 and for a threshold of 4 ng/ml were
0.701 and 0.970, respectively. These values are very sim-
ilar to the main analysis indicating missing height and
diabetes data were unlikely to have biased the result.
Discussion
This study has shown that in men aged 50–69 in the UK
there is an inverse relationship between PSA and BMI, and a
positive relationship between age and PSA. The magnitude
and direction of effect of these relationships is consistent
with previous research [15, 18–23]. In previous research,
Table 4 Averaged sensitivities and specificities for prostate cancer detection at biopsy for different models from tenfold cross-validation
Model Threshold 3.0 ng/ml Threshold 4.0 ng/ml
Proportion of cases above
threshold (SD)
Proportion of controls below
threshold (SD)
Proportion of cases above
threshold (SD)
Proportion of controls below
threshold (SD)
PSA 1 (0) 0.931 (0.011) 0.687 (0.022) 0.964 (0.005)
Age–PSA 0.946 (0.019) 0.933 (0.008) 0.699 (0.028) 0.968 (0.005)
BMI–PSA 0.978 (0.008) 0.932 (0.010) 0.683 (0.020) 0.965 (0.005)
Age–BMI–
PSA
0.977 (0.008) 0.932 (0.010) 0.706 (0.028) 0.967 (0.005)
NICE
guidelinesa
– – 0.798 (0.017) 0.958 (0.006)
PSA prostate-specific antigen, BMI body mass index
a NICE guidelines–ages 50–59: 3.0 ng/ml, ages 60–69: 4.0 ng/ml
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however, the relationship between BMI and PSA may have
been assumed to be additive; this study considered the
relationship to likely be multiplicative and has presented the
results as such. This interpretation fits better with the pro-
posed theories of why BMI may be associated with PSA.
Overall, adjusting for BMI did not materially improve
the discrimination of PSA for detecting prostate cancer, as
there was no evidence the NICE guidelines for screening
for prostate cancer using age-band-specific PSA thresholds
performed worse than our age-, BMI-, and age–BMI-ad-
justed PSA models. It is unlikely that the associations seen
between age, BMI, and PSA are solely the result of asso-
ciations with prostate cancer, as the likelihood tests showed
no evidence that the results from men with a PSA less than
3.0 ng/ml (not biopsied) were different from men with a
PSA more than 3.0 ng/ml (biopsied).
It is not clear from this study whether there is a causal
relationship between BMI and PSA—the relationships
between BMI, PSA, and prostate cancer are complex, and
as not all men were biopsied it is impossible to disentangle
relationships with underlying prostate cancer. Even if all
men were biopsied, there would still be a risk of false
negatives from missing the cancer on the biopsy [37, 38].
This, combined with the use of PSA testing as a means of
screening for prostate cancer in general practice (as well as
any variables which affect the overall risk of receiving a
PSA test), makes it difficult for any study to examine the
relationships surrounding PSA and prostate cancer risk.
The limitations of this study are recognized. The study
population is large and taken from multiple centers across
the UK, but will not necessarily be demographically
diverse or applicable to other populations as almost all men
classified themselves as ‘‘white’’ ethnicity. Although the
tenfold cross-validation show very similar results to the
main analysis, these results were not replicated in an
external dataset. However, as internal validation usually
shows some measure of overfitting, the conclusion that the
NICE guidelines show better discrimination for prostate
cancer should be robust.
PSA values were only taken on one day, but PSA levels
are influenced by factors such as biological [43] or labo-
ratory variation [44], inflammation [15] or infection [45].
Some evidence exists for seasonal variation in PSA [46];
however, a study using ProtecT data showed no variation in
PSA due to time of year or amount of sunlight per day [47]
and thus time of year should not have affected these results.
As not all men were biopsied, the calculated specificities
and sensitivities are likely overestimates as there were
likely to be men with undiagnosed prostate cancer (Box 2).
ROC curves and AUCs could not be generated as a result,
and these results should not be compared with the true
sensitivity and specificity of PSA as a test for detecting
prostate cancer.
Height data were self-reported; this may have slightly
biased the results if taller or shorter men were more likely
to misreport their height. Additionally, a large number of
men did not have a recorded height as they did not par-
ticipate in the additional study that recorded height data;
data were likely to be missing at random (i.e., it is unlikely
that taller men were more likely to have missing height
data). Multiple imputations showed that missing height
data were unlikely to have biased the analysis as the
models were very similar.
Men with diabetes were not included in the model, as
BMI is a recognized risk factor for diabetes, and diabetes is
associated with a lower PSA [48] and prostate cancer [36],
so men with diabetes may obscure the relationship between
BMI and PSA. Although there is conflicting evidence,
smoking [49], exercise [50], and a low-fat diet [51] have all
been associated with decreased PSA and BMI, and high
alcohol intake and benign prostatic hypertrophy [52] have
been associated with increased PSA and BMI [53]. These
variables were not considered in this study, but these
associations would indicate a positive relationship between
BMI and PSA which is not observed in this study; thus, it is
unlikely that the observed BMI–PSA relationship was
biased away from the null by any of these variables.
Conclusions
This study has described the relationship between age and
BMI and PSA in men without diabetes. These relationships
were used to adjust PSA to examine the potential clinical
utility of an age–BMI-adjusted PSA, but this did not per-
form better than current NICE guidelines. More studies
examining the effects of variables on PSA, independent of
the effect on prostate cancer, could help to improve PSA
testing for prostate cancer.
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